ArticleJournal of pain research2025
Identifying Diagnostic Biomarkers for Electroacupuncture Treatment of Rheumatoid Arthritis Using Bioinformatic Analysis and Machine Learning Algorithms.
Article in Journal of pain research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ARHGAP17 and VEGFB as Biomarkers for Electroacupuncture in Rheumatoid Arthritis: Potential and Unresolved Questions [Letter].Journal of pain research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Rheumatoid arthritis (RA) is a persistent inflammatory condition, and electroacupuncture (EA) has been demonstrated to effectively reduce the symptoms associated with RA. However, the molecular mechanisms underlying the effects of EA in RA remained poorly understood. This study aimed to identify potential diagnostic biomarkers for RA and elucidated the molecular targets of EA by using bioinformatics analysis and machine learning algorithms in peripheral blood samples. Methods: We obtained datasets from the Gene Expression Omnibus(GEO) database containing samples from RA patients (GSE15573) and from RA patients after EA treatment (GSE59526) for bioinformatics analysis. Diagnostic biomarkers were identified using three distinct machine learning algorithms (LASSO, Random Forest and SVM-REF). A rat model of RA was established using Complete Freund's Adjuvant (CFA), and quantitative real-time PCR was performed to confirm the differential expression of identified diagnostic biomarkers and assess the modulatory impact of EA on these genes. Results: Twenty-six genes were identified as differentially expressed following EA treatment. Three machine learning algorithms converged on ARHGAP17 and VEGFB as potential diagnostic biomarkers for RA, exhibiting robust diagnostic performance (AUC > 0.75) and consistent expression patterns across multiple RA cohorts (GSE17755, GSE205962 and GSE93272). Besides, EA treatment significantly increased the paw withdrawal threshold (PWT) and the peripheral blood expression of both ARHGAP17 and VEGFB in CFA rats. Conclusion: This study employed three machine learning algorithms to identify potential diagnostic biomarkers for the alleviation of RA by EA. The biomarkers demonstrated robust diagnostic performance across multiple validation datasets. Furthermore, animal experiments confirmed that EA exerted a favorable regulatory effect on these diagnostic biomarkers. The findings of this study provided novel therapeutic targets for the EA treatment of RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.